Global Health & Emerging Pathogens Institute
The Global Health and Emerging Pathogens Institute is the nucleus of Mount Sinai’s work on infectious diseases and the pathogens that cause them. The Institute, based in New York City, builds on Mount Sinai’s internationally recognized expertise in RNA virus research and encompasses ongoing research on the molecular pathogenesis of influenza, HIV, and dengue and Ebola viruses, as well as on hepatitis C.
The innate component of the immune response is a rapid one, in which the body recognizes and fights off general classes of infectious agents. Mount Sinai has been at the forefront of current research, identifying viral factors that inhibit innate immune responses and showing how such factors contribute to the pathogenesis of the virus. Global Health and Emerging Pathogens Institute expertise in virology will prove invaluable as we work to develop robust vaccines and antiviral drugs.
The Global Health and Emerging Pathogens Institute is focused on expanding Mount Sinai’s world-renowned programs in RNA viruses. Our strategy serves as a model for developing new programs to study other RNA viruses, such as hepatitis C. Hepatitis C is an obvious focus for expanding pathogenesis research given the growing prevalence of this infection. Other viruses of possible interest include West Nile virus and certain RNA viruses that could potentially be used as bioterrorist agents.
The Institute is also developing research programs driven by local and global public health needs. One emerging area of interest is antibiotic resistance, which has become a serious threat to hospitalized patients. Our antibiotic resistance program will leverage Mount Sinai’s abundant clinical and patient resources, and its global health initiatives will encompass training as well as basic and clinical research.
For more information:
Last Update: March 21, 2012